<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190701044062N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-10-11</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of ANCIL on diabetic foot wounds</public_title>
      <acronym></acronym>
      <scientific_title>Effect of ANSIL(Silver nanoparticles) solution on Diabetic foot wounds: A double-blind clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-10-16</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56900</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Randomization will be performed using simple randomization using GraphPad software and by a secretary who does not interfere with other stages of the investigation. People will be randomly divided into groups A, B, C, D, Blinding description: A solution that has an active ingredient in ANCIL with a solution that does not have a substance and is used as a placebo is completely identical in terms of the shape and size of the container, and the solution themselves do not differ in terms of odor and color, and are completely indistinguishable. (This action was taken by the manufacturer company of the solution). The important point is that the patient is told that the solution used for the patient may be medication or medication. Clinicians or outcome assessors and blind patients will be blinded.</study_design>
      <phase>3</phase>
      <hc_freetext>Diabetic foot ulcers.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 20 patients with diabetic foot ulcer receive50ppm of ANCIL solution twice a day for 28days and bandaged on the wound.                     ANCIL solution: ASEPE company introduces ANSIL for the treatment and repair of damaged tissues caused by diabetic wounds, bedsores, and injuries caused by severe burns. Various substances are used in the solution, including plant extracts of silymarin, zinc oxide, silver, ascorbic acid, glycerin, alpha tocopherol, retinoids, and phylloquinone. The type of material and their composition determine that it has the greatest effect on wound healing and strengthening. Intervention 2: Intervention group: 20 patients with diabetic foot ulcer receive100ppm of ANCIL solution twice a day for 28days and bandaged on the wound.             ANCIL solution: ASEPE company introduces ANSIL for the treatment and repair of damaged tissues caused by diabetic wounds, bedsores, and injuries caused by severe burns. Various substances are used in the solution, including plant extracts of silymarin, zinc oxide, silver, ascorbic acid, glycerin, alpha tocopherol, retinoids, and phylloquinone. The type of material and their composition determine that it has the greatest effect on wound healing and strengthening. Intervention 3: Intervention group: 20 patients with diabetic foot ulcer receive150ppm of ANCIL solution twice a day for 30 days and bandaged on the wound.                      ANCIL solution: ASEPE company introduces ANSIL for the treatment and repair of damaged tissues caused by diabetic wounds, bedsores, and injuries caused by severe burns. Various substances are used in the solution, including plant extracts of silymarin, zinc oxide, silver, ascorbic acid, glycerin, alpha tocopherol, retinoids, and phylloquinone. The type of material and their composition determine that it has the greatest effect on wound healing and strengthening. Intervention 4: Control group: Treatment of diabetic foot ulcers in 20 patients in a way other than the mentioned method for 28days.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
A portion of the data will be shared.

When:
2023-2024

To whom:
Researchers and academic staffs

Conditions:
For further studies

Where to obtain:
Request via email: Khademishima94@gmail.com
Shima Khademi

How to obtain:
Request via email: Khademishima94@gmail.com
Shima Khademi

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shima Khademi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No1026,East Second floor, Azarabadegan Ave, Third daneshgah Ave, Nasr Town</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5158375751</zip>
        <telephone>+98 41 3662 8155</telephone>
        <email>Khademishima94@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Manouchehr Khoshbaten</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht Street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166/15731</zip>
        <telephone>+98 41 1334 3010</telephone>
        <email>mkhoshbaten@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diabetic patients taking insulin with diabetic wound
Age range 18 to 80 years</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with infectious wounds
Sensitivity to topical formulations
Patients who need surgery for their wounds</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z86.31</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Personal history of diabetic foot ulcer</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 20 patients with diabetic foot ulcer receive50ppm of ANCIL solution twice a day for 28days and bandaged on the wound.                     ANCIL solution: ASEPE company introduces ANSIL for the treatment and repair of damaged tissues caused by diabetic wounds, bedsores, and injuries caused by severe burns. Various substances are used in the solution, including plant extracts of silymarin, zinc oxide, silver, ascorbic acid, glycerin, alpha tocopherol, retinoids, and phylloquinone. The type of material and their composition determine that it has the greatest effect on wound healing and strengthening.</i_keyword>
      <i_keyword>Intervention group: 20 patients with diabetic foot ulcer receive100ppm of ANCIL solution twice a day for 28days and bandaged on the wound.             ANCIL solution: ASEPE company introduces ANSIL for the treatment and repair of damaged tissues caused by diabetic wounds, bedsores, and injuries caused by severe burns. Various substances are used in the solution, including plant extracts of silymarin, zinc oxide, silver, ascorbic acid, glycerin, alpha tocopherol, retinoids, and phylloquinone. The type of material and their composition determine that it has the greatest effect on wound healing and strengthening.</i_keyword>
      <i_keyword>Intervention group: 20 patients with diabetic foot ulcer receive150ppm of ANCIL solution twice a day for 30 days and bandaged on the wound.                      ANCIL solution: ASEPE company introduces ANSIL for the treatment and repair of damaged tissues caused by diabetic wounds, bedsores, and injuries caused by severe burns. Various substances are used in the solution, including plant extracts of silymarin, zinc oxide, silver, ascorbic acid, glycerin, alpha tocopherol, retinoids, and phylloquinone. The type of material and their composition determine that it has the greatest effect on wound healing and strengthening.</i_keyword>
      <i_keyword>Control group: Treatment of diabetic foot ulcers in 20 patients in a way other than the mentioned method for 28days</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The severity of a diabetic foot ulcer is measured using the Texas Scoring System. Timepoint: Before the intervention and 7, 14, 21, and 28 days after the intervention. Method of measurement: The severity of diabetic foot ulcers in patients receiving ANCIL and placebo solution before the intervention and on days 7, 14, 21, and 28 after the intervention is measured using the Texas scoring system. Texas scoring system for diabetic foot ulcers to 4 degrees (0 to 3 Grade 1 is classified according to wound depth, infection, and ischemia as Grade 0 before or after the wound has healed, Grade 1 of a superficial wound that has not involved a tendon, capsule, or bone. Grade 2: The wound has penetrated a tendon or capsule. Grade 3: The wound has penetrated the bone or joint. Stage A: clean wound, Stage B: non-infectious and non-ischemic, Stage C: ischemic and non-ischemic, Stage D: Infectious and ischemic wound.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-03-15</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medic</contact_name>
        <contact_address>Central Office of Tabriz University of Medical Sciences Tabriz -Golghast St.- Azadi St. Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
